Tüdőrák: vizsgálatok itt: Spanyolország

273 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.

• 4. fázisTaking people
  Dabrafenib and/or Trametinib Rollover Study

  Where

  Barcelona, Madrid, Valencia

  Életkor

  18 év to 100 év

  People

  100 worldwide

  Run by

  Novartis Pharmaceuticals

  See details and how to joinNCT03340506 · EU 2023-509318-13-00
• 3. fázisTaking people
  LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

  Where

  Barcelona, Elche, Lleida, Madrid, Málaga, Pamplona, Seville, Torrejón de Ardoz

  Életkor

  18 év and over

  People

  734 worldwide

  Run by

  NovoCure GmbH

  See details and how to joinNCT06216301
• 3. fázisTaking people
  A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

  Where

  Barcelona, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Pozuelo de Alarcón, Santiago de Compostela

  Életkor

  18 év and over

  People

  780 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06312137 · EU 2023-508012-35-00
• 3. fázisTaking people
  A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  Where

  Barcelona, Las Palmas de Gran Canaria, Leganés, Madrid, Málaga, Sevilla, Vic

  Életkor

  18 év and over

  People

  348 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06345729 · EU 2023-507776-42-00
• 3. fázisTaking people
  A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

  Where

  Barcelona, Jaén, Madrid, Majadahonda, Santiago de Compostela, Sevilla, Valencia

  Életkor

  18 év and over

  People

  530 worldwide

  Run by

  Bristol-Myers Squibb

  See details and how to joinNCT06646276 · EU 2024-515740-23-00
• 1/2. fázisTaking people
  A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

  Where

  Barcelona, Logroño, Madrid

  Életkor

  18 év and over

  People

  616 worldwide

  Run by

  Verastem, Inc.

  See details and how to joinNCT07020221
• 3. fázisTaking people
  A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

  Where

  Barcelona, Las Palmas de Gran Canar, L'Hospitalet de Llobrega, Madrid, Santander

  Életkor

  18 év and over

  People

  420 worldwide

  Run by

  GlaxoSmithKline

  See details and how to joinNCT07099898
• 3. fázisTaking people
  A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

  Where

  A Coruña, Badalona, Barcelona, Madrid, Majadahonda, Sevilla, Valencia

  Életkor

  18 év and over

  People

  675 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT07190248 · EU 2024-514500-14-00
• 2. fázisTaking people
  KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

  Where

  Pozuelo de Alarcón, Sevilla

  Életkor

  18 év and over

  People

  140 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT07252739 · EU 2025-521939-36-00
• 3. fázisTaking people
  Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  Where

  A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Sevilla, Zaragoza

  Életkor

  18 év and over

  People

  400 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT07291037 · EU 2024-520101-39-00
• 3. fázisTaking people
  MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

  Where

  Barcelona, Girona, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga, Pozuelo de Alarcón, Sevilla

  Életkor

  18 év and over

  People

  400 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT07431827 · EU 2024-517337-41-00
• 3. fázisTaking people
  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  Where

  A Coruña, Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Palma, Pamplona, San Cristóbal de La Laguna, Sevilla, Valencia, Zaragoza

  Életkor

  18 év and over

  People

  670 worldwide

  Run by

  Boehringer Ingelheim

  See details and how to joinNCT07472517 · EU 2025-520565-51-00
• 1. fázisTaking people
  A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

  Where

  Logrono, Madrid, Valencia

  Életkor

  18 év and over

  People

  150 worldwide

  Run by

  IDEAYA Biosciences

  See details and how to joinNCT07503808 · EU 2026-526299-21-00
• 3. fázisTaking people
  A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

  Where

  Barcelona, Girona, Madrid, Sevilla, Valencia

  Életkor

  18 év and over

  People

  310 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT07554339 · EU 2025-522038-29-00
• 3. fázisTaking people
  Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

  Where

  A Coruña, Jaén, Jerez de la Frontera, Madrid, Majadahonda, Málaga, Seville, Valencia

  Életkor

  18 év and over

  People

  850 worldwide

  Run by

  Bristol-Myers Squibb

  See details and how to joinNCT07680790 · EU 2026-526486-21-00
• 1/2. fázisTaking people
  A Study of DS-3939a in Participants With Solid Tumors

  Where

  Barcelona, Lleida, Madrid, Málaga, Santiago de Compostela, Seville

  Életkor

  18 év and over

  People

  400 worldwide

  Run by

  Daiichi Sankyo

  See details and how to joinNCT07739966 · EU 2026-525218-75-00
• 1/2. fázisTaking people
  A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)

  Where

  Barcelona, Madrid, Valencia

  Életkor

  18 év and over

  People

  55 worldwide

  Run by

  Boehringer Ingelheim

  See details and how to joinNCT07843940 · EU 2026-525459-99-00
• 1. fázisNot yet taking people in Spanyolország
  A Study of LY4336619 in Adult Participants With Advanced Solid Tumors

  Where

  Barcelona, Madrid

  Életkor

  18 év and over

  People

  370 worldwide

  Run by

  Eli Lilly and Company

  See details and how to joinNCT07928258 · EU 2026-526553-33-00
• 3. fázisTaking people
  A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

  Where

  A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Palma, Sevilla, Valencia

  Életkor

  18 év and over

  People

  1000 worldwide

  Run by

  Bristol-Myers Squibb

  See details and how to joinNCT06561386 · EU 2024-513682-40-01
• 3. fázisTaking people
  A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  Where

  A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga, Pozuelo de Alarcón

  Életkor

  18 év and over

  People

  680 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT06623422 · EU 2023-506327-29-00
• No phaseTaking people
  General Anesthesia vs Conscious Sedation for Radial Endobronchial Ultrasound

  Where

  Oviedo

  Életkor

  18 év and over

  People

  306 worldwide

  Run by

  Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

  See details and how to joinNCT06950515
• 1/2. fázisTaking people
  A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

  Where

  Barcelona, Las Palmas de Gran Canaria, Logrono, Madrid

  Életkor

  18 év to 64 év

  People

  170 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT07227597 · EU 2025-521032-11-00
• 2. fázisTaking people
  Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

  Where

  Barcelona, Madrid, Sevilla

  Életkor

  18 év and over

  People

  60 worldwide

  Run by

  Boehringer Ingelheim

  See details and how to joinNCT07486817 · EU 2025-523567-38-00
• 3. fázisTaking people
  A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

  Where

  Badajoz, Barakaldo, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Sevilla, Valencia

  Életkor

  18 év and over

  People

  876 worldwide

  Run by

  Merck Sharp & Dohme LLC

  See details and how to joinNCT07513376 · EU 2025-522643-18-00
• 3. fázisTaking people
  A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

  Where

  A Coruña, Badalona, Barcelona, Bilbao, Granada, Lleida, Madrid, Majadahonda, Málaga, Palma, Reus, Sabadell, Santa Cruz de Tenerife, Sant Joan d'Alacant, Sevilla, Valencia, Zaragoza

  Életkor

  18 év and over

  People

  400 worldwide

  Run by

  Hoffmann-La Roche

  See details and how to joinNCT07541170 · EU 2025-524263-21-01